Survodutide is sold here for laboratory research, in 1 size (10mg), starting at $160.00 a vial. Every batch arrives with a certificate naming the test that identified it, the test that measured its purity, and the date each was run. It is not an FDA-approved medicine. Research use only, and never for people or animals.
Survodutide specifications
| Product name | Survodutide |
|---|---|
| Formula | C192H289N47O61 |
| Physical form | Freeze-dried powder — a solid cake in a sealed vial |
| Appearance | White to off-white cake |
| Sizes on this page | 10mg |
| Purity specification | ≥99% by RP-HPLC. The number for the lot you receive is whatever its own certificate says. |
| Identity check | Mass spectrometry, read against the mass this compound should have |
| Net content | Weighed per lot and reported separately from purity |
| Lot documentation | At the laboratory — each certificate posts here the day it clears |
| Storage | Sealed, cold and out of the light |
| Ships from | Santa Ana, California — same business day on verified in-stock orders placed before 12 PM Pacific |
| Intended use | Laboratory research only. Not for human or animal use. |
What is Survodutide, and what is it used for?
Supplier lists write it as peptide Survodutide; every one of those is this record, and the lot certificate further down counts for more than the wording on a label.
Chemically: molecular formula C192H289N47O61, average mass 4232 g/mol (PubChem CID 171378821). Those figures are what the identity test on a certificate is read against.
Dual glucagon receptor and GLP-1 receptor agonist peptide, developed as BI 456906.
Agonist at both the glucagon receptor (GCGR) and the GLP-1 receptor. The two-arm design follows the same logic as retatrutide's glucagon arm: GLP-1 receptor agonism acts on calorie intake, glucagon receptor agonism acts on energy expenditure and hepatic metabolism.
Investigational, developed by Boehringer Ingelheim. Studied in phase II randomised placebo-controlled trials in type 2 diabetes and in metabolic liver disease.
No approved product. Adverse events, predominantly gastrointestinal, were reported at a substantially higher rate than for the comparator in the published phase II trial.
Survodutide for sale: 10mg vials, price per mg
Survodutide is sold in 1 size here, 10mg, from $160.00 a vial. The per-mg column is the honest comparison between sizes; the two tier columns show what ten and twenty vials of one size bill at, because the volume discount is per size and mixed sizes do not combine.
| Size | One vial | Per mg | 10 vials −10% | 20 vials −15% | Availability |
|---|---|---|---|---|---|
| Survodutide 10mg | $160.00 | $16.00 | $1,440.00$14.40/mg | $2,720.00$13.60/mg | Backordered — waitlist |
Survodutide discounts: bulk pricing, Subscribe & Save, and codes
Three things move this price and nothing else does: how many vials of one size are on the order, whether that order repeats, and one code. The fourth column prices each route against the 10mg vial.
| Buying option | Takes off | When it applies | 10mg at this option |
|---|---|---|---|
| One vial, one time | — | Any order | $160.00 |
| 10–19 vials of one size | 10% | This order | $1,440.00$144.00 a vial |
| 20 vials of one size | 15% | This order | $2,720.00$136.00 a vial |
| Subscribe, every 1 month | 6% | Shipment 2 onward | First $160.00, then $150.40 |
| Subscribe, every 2 months | 4% | Shipment 2 onward | First $160.00, then $153.60 |
| Subscribe, every 3 months | 2% | Shipment 2 onward | First $160.00, then $156.80 |
| 10 vials on a monthly subscription | 10%, then 6% more | Shipment 2 onward | First $1,440.00, then $1,353.60 |
| Sign-up code | 10% of the order | One use, dead 24 hours after signup | $144.00 for one vial |
| Friday newsletter code | 5% of the order | Live 24 hours, a new one each Friday | $152.00 for one vial |
| On-site offer code | 5% of the order | Live 30 minutes from when it appears | $152.00 for one vial |
| Free standard shipping | The shipping charge | Orders over $200 | 2 vials |
The first three stack; the codes do not. A volume discount comes off the line, a subscription cadence comes off that same line from shipment 2, and one code comes off what is left. One code per order, never two. A subscription runs a minimum of two shipments and can be cancelled once the second has shipped, and the first shipment always bills at today's eligible price with no cadence discount on it. The lowest this record ever bills is $12.78 per mg: twenty 10mg vials on a monthly subscription, from shipment 2 onward.
Every figure above is what you pay; nothing is added at checkout — dispatch and delivery work the same on every order.
Where to buy Survodutide: five checks before you order from anyone
Survodutide for sale, or Survodutide peptide for sale, means this page: one record, 1 size, a lot certificate for each. You can buy Survodutide online here with guest checkout; verified in-stock orders placed before 12 PM Pacific are dispatched the same day.
Run these on us too. A supplier who cannot pass them is asking you to take their word for it, and their word is the one thing a certificate exists to replace.
- Check the certificate on the lab’s own site, not ours.
- See whether it was written for the seller.
- Match the lot number on the paper to the one on the vial.
- Look for a method and a date next to every number.
- Make sure identity was tested, not assumed.
Each of those is worked through, with what a failed check actually looks like, on verifying a certificate.
Survodutide vs Tirzepatide and Semaglutide: different molecules, separate records
Survodutide vs Tirzepatide, or Tirzepatide vs Survodutide, is the comparison people search most, with Semaglutide close behind, and they are not the same thing. Each is a different molecule with a different formula, mass and research record, and each has its own certificate here.
Tirzepatide vs Survodutide: the same comparison, side by side
| Record | Class | Formula | Avg. mass | Sizes here |
|---|---|---|---|---|
| Survodutide | Dual glucagon receptor and GLP-1 receptor agonist peptide, developed as BI 456906. | C192H289N47O61 | 4232 | 10mg from $160.00 |
| Tirzepatide | A peptide that works on the GIP and GLP-1 receptors at the same time. | C225H348N48O68 | 4813 | 5mg · 10mg · 15mg · 20mg · 30mg · 40mg · 50mg · 60mg · 70mg · 80mg · 90mg · 100mg · 110mg · 120mg from $50.00 |
| Semaglutide | A peptide that works on the GLP-1 receptor. | C187H291N45O59 | 4114 | 5mg · 10mg · 15mg · 20mg · 30mg from $80.00 |
Documentation compared in full: Survodutide vs Tirzepatide, side by side · Survodutide vs Semaglutide, side by side.
The Survodutide certificate: lot, purity, identity, and how to verify it
A certificate answers identity, purity and net content as three separate questions, each with the method that produced it and the date it was run — how to read one covers what each field does and does not cover. For Survodutide that means a mass spectrum landing on 4,232 g/mol for C192H289N47O61, the figure published against PubChem CID 171378821.
The certificate below belongs to one lot, and its number matches the one printed on the vial you receive. A real report for a different batch is still the wrong report.
| Size | Lot | Identity method | Purity | Test date |
|---|---|---|---|---|
| 10mg | Pending verification | Pending verification | Pending verification | Pending verification |
No lot documentation is published for Survodutide yet. Rather than display a placeholder certificate, this record shows the gap until each field has been verified against the lot in hand. The certificate index lists every lot the moment its report clears.
Solution arithmetic for the bench, with no administration guidance: the vial concentration calculator, preset to Survodutide.
Where the FDA stands on Survodutide
The FDA has not approved this compound for anything, and nothing in this catalogue is a medicine. Where a compound stands legally depends on what it is, what form it is in, what it is being used for and which country you are in, and it changes over time, so the status shown here carries the date it was last checked.
Status verified 2026-08-25. Regulatory positions move; check the primary source before relying on any summary, including this one.
It is sold here as laboratory material under the research-use restriction that closes this page, which is not an approval, and not a statement that the compound is safe, effective or right for any purpose.
Survodutide research: what the published studies examine
Status: No FDA-approved application. This compound is sold as laboratory material. Where research on it has been published, it sits at the animal, cell or early-human stage, and this record does not summarise what it found. A supplier is not a neutral judge of evidence about its own catalogue.
Survodutide is a dual agonist at the glucagon receptor and the GLP-1 receptor. It is worth positioning it against the other multi-receptor incretins on this catalogue, because the receptor sets differ in ways that matter: tirzepatide pairs GLP-1 with GIP, survodutide pairs GLP-1 with glucagon, and retatrutide combines all three. The glucagon arm is the one survodutide shares with retatrutide and the one that distinguishes both from tirzepatide, and it is proposed to act on energy expenditure and hepatic fat handling rather than on calorie intake.
Glucagon receptor agonism is also the least established of the three arms across this whole class, and adding it is a genuine pharmacological bet rather than an obvious improvement.
| Reported observation | Model | Source |
|---|---|---|
| In a phase II randomised, double-blind, placebo-controlled parallel-group trial of 413 participants with type 2 diabetes on background metformin, with an open-label semaglutide comparator arm, adverse events were reported for 77.8% of survodutide-treated participants — mainly gastrointestinal — against 52.5% receiving placebo and 52.0% receiving semaglutide. The authors state that dose-related gastrointestinal adverse events could be mitigated with slower dose escalation. | phase II randomised double-blind placebo-controlled trial, 413 adults with type 2 diabetes, active comparator | Bluher and colleagues, Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial, Diabetologia (2023)Sponsor-funded (Boehringer Ingelheim) with academic investigators. Cited here for the tolerability data; the efficacy endpoints are deliberately not reproduced. |
Open questions. The tolerability figure above is the most decision-relevant published fact about this compound and it is the one supplier copy omits: adverse events in roughly three-quarters of treated participants against about half on placebo and about half on the active comparator, predominantly gastrointestinal and dose-related. The compound is investigational with no approval anywhere, and the glucagon receptor arm — the feature that distinguishes it — is the least characterised part of the multi-receptor incretin story generally.
Glucagon receptor agonism raises hepatic glucose output as a matter of basic physiology, which is why these molecules pair it with GLP-1 rather than using it alone, and the net effect depends on that balance holding. This page does not reproduce clinical efficacy endpoints.
That is a deliberate and consistent choice across every incretin compound on this catalogue: those results describe a supervised therapy given to patients under medical care, which is a different thing from laboratory material, and printing them beside a purchase control would blur that distinction rather than inform anyone. Tolerability findings from the same trials are reported, because how often a compound causes adverse events is a property of the compound.
Finally, the point that applies to every reseller including this one: a vial bearing one of these names is related to the developed molecule by claimed sequence identity alone, and that claim is exactly what an identity assay on the specific lot exists to test.
Each row above describes an observation in the stated model. None of it describes what Survodutide would do in a person or an animal outside that model, and none of it is a recommendation to use it for anything.
Questions about Survodutide
Where to buy Survodutide Peptide, and can I get it online?
How much does Survodutide Peptide cost?
What is the cheapest way to buy Survodutide Peptide?
What is the FDA approval status of Survodutide?
What is Survodutide used for?
Is Survodutide legal?
What is the difference between Survodutide and Tirzepatide?
How does Survodutide work, and what does it do?
What is Survodutide peptide?
Is Survodutide fda approved?
How do I verify the certificate of analysis is real?
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
